CDK4 and small cell lung carcinoma: Moreover, we found that CDK6 is the major upregulated factor during the resistance period of SCLC chemotherapy, and CDK4/6 inhibitors significantly abolished CDK6 protein upregulation in SCLC chemotherapy‐resistant cells (H69AR & H446DDP).